Russia's RusNano and the UK's Xenetic Biosciences explore joint projects in biotech sector

12 September 2011

In a second Anglo/Russian research collaboration announced to coincide with UK Prime Minister David Cameron's official visit to Russia, Human Stem Cell Institute (RusNano; Russian Corporation of Nanotechnologies) and Britian’s Xenetic Biosciences (AIM: XEN) met to discuss opportunities for further collaboration and investment in the international biotech sector.

This follows on from the announcement last month that RusNano and Xenetic (formerly Lipoxen) were the initiators of a major cross-border M&A transaction to form SynBio, with additional financing secured from Russia's State Venture Fund RusNano (The Pharma Letter August 9). The deal, which is expected to complete by the end of September, was acknowledged at the time as an exceptional example of UK-Russian cooperation, and it is now the intention of the two companies to pursue opportunities to extend their cooperation both within and beyond SynBio.

Furthers global ambitions of Russian group

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK